Robert F. Kennedy Jr. has built a career on one sentence: don't trust the regulators. Now he runs the regulators, and his first big move on peptides is to trust them even less, by telling them to look away.
The draft policy would let compounding pharmacies make BPC-157, TB-500, epitalon, MOTS-c, KPV and semax. HHS concedes in the same breath that none is FDA-approved and that the policy establishes nothing about safety or effectiveness. FDA scientists said the evidence was insufficient. So the department's position is that no one knows whether these work, no one knows whether they harm, and enforcement is suspended anyway. Call it a regulatory shrug in a lab coat.
The best defense is harm reduction, and it deserves a real answer, because harm reduction is a value the Left holds. People are already injecting gray-market peptides sold as "research chemicals" by anonymous websites and gym influencers. A prescription, a licensed pharmacy and quality testing sound better than a vial of unknown powder in the mail. If the choice were only between those two, I'd take the pharmacy.
But that isn't the choice. Harm reduction means meeting people where they are while preserving the thing that protects them. Needle exchanges don't tell the public that heroin is medicine. This policy does the reverse. It confers the look of medical legitimacy, a doctor's signature and a pharmacy label, on substances that never passed the test that gives such legitimacy meaning. A patient who gets BPC-157 from a pharmacist will reasonably assume someone checked it. Someone did. The people who checked said the evidence wasn't there.
And consider who benefits. Not the patient, who gets no better data. Not science, since a product legally sold has little reason to fund a trial that might show it doesn't work. The winners are compounding pharmacies, telehealth outfits and wellness clinics that can now sell expensive, unapproved, cash-pay injections with a government shield. This is a business opportunity dressed up as liberty.
We have seen what happens when the compounding sector gets benefit of the doubt. In 2012, contaminated steroid injections from the New England Compounding Center caused a fungal meningitis outbreak that killed dozens and sickened hundreds. Congress responded with the 2013 Drug Quality and Security Act, which created the framework Kennedy is now stretching. The bulks list exists because "made by a pharmacist" is not a safety guarantee. Promises of traceability and testing matter only if an agency has the staff and will to enforce them. This administration has spent a year gutting the very health agencies that would do that work.
The hypocrisy is the part that should make everyone furious. The same department that treats decades of vaccine data as suspect, and demands ever more proof from a product with a track record measured in billions of doses, is waving through six compounds with almost no human evidence behind them. Skepticism is supposed to be a principle. Here it is a mood, applied to products that annoy Kennedy's allies and dropped for products his constituency likes. Evidence is not a thing you require only of your enemies.
Democrats should resist the lazy move of mocking the wellness crowd. Many of those people distrust the system because the system has burned them: opaque pricing, drug-company marketing, doctors who rush them out the door. That distrust is earned. But the answer to a health system that profits off people's desperation is not a deregulated one that profits off their hope. Real reform would be cheaper care, faster trials, and honest regulators who explain themselves.
If these peptides work, prove it. That's the whole job. Kennedy has found a way to give people the feeling of medicine while skipping the part that makes it medicine, and he calls it freedom.
How it may affect me
A prescription for these peptides would not mean they have been proven safe or effective. If you're considering one, ask the prescriber what human evidence exists, which pharmacy makes it and whether it is independently tested. Report side effects to FDA's MedWatch. Competitive athletes should know that BPC-157 is banned by the World Anti-Doping Agency. Insurance is unlikely to cover unapproved compounds.
